Acumen Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
Acumen Pharmaceuticals, Inc. (ABOS) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2026-06-30 was $0.00.
- Acumen Pharmaceuticals, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2026-03-31 was $0.00.
- Acumen Pharmaceuticals, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-12-31 was $100.00K.
- Acumen Pharmaceuticals, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Acumen Pharmaceuticals, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2025 was $100.00K, a 0.00% change from fiscal 2024.
- Acumen Pharmaceuticals, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2024 was $100.00K.
- Acumen Pharmaceuticals, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2023 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $100.00K derived: sum of 3 quarters · filed 2026-08-12 | $100.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $100.00K derived: sum of 2 quarters · filed 2026-05-12 | $100.00K derived: sum of 3 quarters · filed 2026-05-12 | $100.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $100.00K derived: sum of 2 quarters · filed 2026-03-26 | $100.00K derived: sum of 3 quarters · filed 2026-08-12 | $100.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $100.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $100.00K derived: sum of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $100.00K derived: sum of 2 quarters · filed 2026-03-26 | $100.00K 10-K · filed 2026-03-26 | |
| 2024-09-30 | $100.00K 10-Q · filed 2025-11-12 | $100.00K 10-Q · filed 2025-11-12 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $0.00 10-K · filed 2025-03-27 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |